Participant characteristics
| . | All . | Males . | Females . |
|---|---|---|---|
| n | 112 | 49 | 63 |
| Age (years) | 15.1 ± 1.2 | 15.3 ± 1.4 | 14.9 ± 1.0 |
| Type 1 diabetes duration (years) | 6.8 ± 3.4 | 6.7 ± 3.4 | 6.8 ± 3.4 |
| Developmental stage | |||
| Prepubertal (Tanner 1) (%) | 0 | 0 | 0 |
| Pubertal (Tanner 2–4) (%) | 38 | 49 | 29 |
| Postpubertal (Tanner 5) (%) | 63 | 51 | 71 |
| zBMI (SDS) | 0.8 ± 0.7 | 0.7 ± 0.8 | 0.9 ± 0.7 |
| Insulin dose (units · kg−1 · day−1) | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 |
| Blood glucose monitoring frequency (checks/day) | 3.6 ± 1.2 | 3.5 ± 1.1 | 3.7 ± 1.2 |
| Insulin treatment plan | |||
| 2 injections/day (%) | 13 | 10 | 14 |
| ≥3 injections/day (%) | 62 | 73 | 52 |
| Insulin pump (%) | 26 | 16 | 33 |
| A1C (%) | 8.7 ± 1.7 | 8.9 ± 1.8 | 8.6 ± 1.7 |
| Missing or restricting insulin (%) | 27 | 24 | 29 |
| . | All . | Males . | Females . |
|---|---|---|---|
| n | 112 | 49 | 63 |
| Age (years) | 15.1 ± 1.2 | 15.3 ± 1.4 | 14.9 ± 1.0 |
| Type 1 diabetes duration (years) | 6.8 ± 3.4 | 6.7 ± 3.4 | 6.8 ± 3.4 |
| Developmental stage | |||
| Prepubertal (Tanner 1) (%) | 0 | 0 | 0 |
| Pubertal (Tanner 2–4) (%) | 38 | 49 | 29 |
| Postpubertal (Tanner 5) (%) | 63 | 51 | 71 |
| zBMI (SDS) | 0.8 ± 0.7 | 0.7 ± 0.8 | 0.9 ± 0.7 |
| Insulin dose (units · kg−1 · day−1) | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 |
| Blood glucose monitoring frequency (checks/day) | 3.6 ± 1.2 | 3.5 ± 1.1 | 3.7 ± 1.2 |
| Insulin treatment plan | |||
| 2 injections/day (%) | 13 | 10 | 14 |
| ≥3 injections/day (%) | 62 | 73 | 52 |
| Insulin pump (%) | 26 | 16 | 33 |
| A1C (%) | 8.7 ± 1.7 | 8.9 ± 1.8 | 8.6 ± 1.7 |
| Missing or restricting insulin (%) | 27 | 24 | 29 |
Data are means ± SD, unless otherwise indicated. SDS, SD score.